To explore the impact of these mutations, CRISPR/Cas9 has been utilized to create ERα-positive breast cancer models where the wild-type ERα gene is replaced with the mutated forms ERαY537S or ERαD538G, allowing researchers to study resistance mechanisms and develop new therapeutic strategies. This evidence concerns the gene ESR1 and breast carcinoma.